Almirall, a global biopharmaceutical company focused on skin health, and IRB Barcelona (the Institute for Research in Biomedicine), an independent, international research centre engaged in fundamental and applied biomedical science, have announced a research collaboration to identify new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs using molecular glue degraders, a novel therapeutic modality.
The proposed treatment uses a new molecular glue degradation modality, providing a different approach to inducing the degradation of potential disease-causing proteins that are unresponsive to conventional treatments.
By combining Almirall
